Reported Tuberculosis in the United States, 2018

Return to Main Menu

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20161

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2016
Reporting Area Total Cases with Therapy Extended2,3 Reasons Therapy was Extended
Rifampin Resistance Adverse Event Nonadherence Treatment Failure Clinically Indicated Other
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
United States 756 60 (7.9) 127 (16.8) 75 (9.9) 5 (0.7) 255 (33.7) 323 (42.7)
Alaska 2 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Arizona 22 5 (22.7) 4 (18.2) 4 (18.2) 0 (0.0) 9 (40.9) 5 (22.7)
Arkansas 7 0 (0.0) 1 (14.3) 3 (42.9) 1 (14.3) 1 (14.3) 1 (14.3)
California 208 21 (10.1) 57 (27.4) 23 (11.1) 3 (1.4) 81 (38.9) 56 (26.9)
Colorado 4 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 2 (50.0) 1 (25.0)
Connecticut 2 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Delaware 1 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
District of Columbia 2 1 (50.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Florida 34 2 (5.9) 1 (2.9) 2 (5.9) 0 (0.0) 21 (61.8) 8 (23.5)
Georgia 25 2 (8.0) 5 (20.0) 2 (8.0) 0 (0.0) 4 (16.0) 19 (76.0)
Hawaii 3 1 (33.3) 0 (0.0) 1 (33.3) 1 (33.3) 0 (0.0) 1 (33.3)
Idaho 0 0 0 0 0 0 0
Illinois 20 1 (5.0) 3 (15.0) 2 (10.0) 0 (0.0) 5 (25.0) 11 (55.0)
Indiana 8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (62.5) 3 (37.5)
Iowa 6 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 5 (83.3)
Kansas 4 0 (0.0) 2 (50.0) 0 (0.0) 0 (0.0) 3 (75.0) 0 (0.0)
Kentucky 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 0 (0.0)
Louisiana 20 0 (0.0) 4 (20.0) 3 (15.0) 0 (0.0) 8 (40.0) 5 (25.0)
Maine 1 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Maryland 17 2 (11.8) 1 (5.9) 1 (5.9) 0 (0.0) 9 (52.9) 6 (35.3)
Massachusetts 24 1 (4.2) 4 (16.7) 0 (0.0) 0 (0.0) 10 (41.7) 9 (37.5)
Michigan 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (66.7) 2 (66.7)
Minnesota 12 7 (58.3) 1 (8.3) 2 (16.7) 0 (0.0) 4 (33.3) 1 (8.3)
Mississippi 6 1 (16.7) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 5 (83.3)
Missouri 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0)
Montana 0 0 0 0 0 0 0
Nebraska 0 0 0 0 0 0 0
Nevada 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
New Hampshire 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
New Jersey 21 1 (4.8) 4 (19.0) 1 (4.8) 0 (0.0) 11 (52.4) 7 (33.3)
New Mexico 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 0 (0.0)
New York State4 16 0 (0.0) 2 (12.5) 2 (12.5) 0 (0.0) 1 (6.3) 11 (68.8)
New York City 35 6 (17.1) 4 (11.4) 10 (28.6) 0 (0.0) 5 (14.3) 10 (28.6)
North Carolina 15 0 (0.0) 4 (26.7) 2 (13.3) 0 (0.0) 4 (26.7) 9 (60.0)
North Dakota 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
Ohio 14 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (14.3) 11 (78.6)
Oklahoma 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0)
Oregon 12 0 (0.0) 1 (8.3) 1 (8.3) 0 (0.0) 6 (50.0) 4 (33.3)
Pennsylvania 26 0 (0.0) 14 (53.8) 3 (11.5) 0 (0.0) 13 (50.0) 5 (19.2)
Rhode Island 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
South Carolina 6 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 3 (50.0)
South Dakota 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Tennessee 8 1 (12.5) 3 (37.5) 1 (12.5) 0 (0.0) 1 (12.5) 2 (25.0)
Texas 119 1 (0.8) 3 (2.5) 5 (4.2) 0 (0.0) 20 (16.8) 102 (85.7)
Utah 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
Vermont 0 0 0 0 0 0 0
Virginia 13 1 (7.7) 1 (7.7) 1 (7.7) 0 (0.0) 6 (46.2) 4 (30.8)
Washington 9 2 (22.2) 1 (11.1) 0 (0.0) 0 (0.0) 3 (33.3) 4 (44.4)
West Virginia 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Wisconsin 5 0 (0.0) 0 (0.0) 2 (40.0) 0 (0.0) 3 (60.0) 0 (0.0)
Wyoming 0 0 0 0 0 0 0
American Samoa5 0 0 0 0 0 0 0
Fed. States of Micronesia5 0 0 0 0 0 0 0
Guam5 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0)
Marshall Islands5 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
N. Mariana Islands5 0 0 0 0 0 0 0
Puerto Rico5 7 0 (0.0) 1 (14.3) 1 (14.3) 0 (0.0) 4 (57.1) 1 (14.3)
Republic of Palau5 1 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
U.S. Virgin Islands5 0 0 0 0 0 0 0

1Most recent year for which data are available.
2Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.
3Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).
4Excludes New York City.
5Not included in U.S. totals.

Note:
Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.